More CLL patients are using Calquence vs Imbruvica

[whmk]

Calquence gaining market share on Imbruvica. More CLL patients are using Calquence vs Imbruvica and it is having an impact on AbbVie stock.

forbes.com/sites/greatspecu...

[country76]

Darn, I should have bought some. lol

[64lusso]

I seem to recall Imbruvica is going off patent in the near future, is it next year?

[bennevisplace in reply to 64lusso]

Abbvie won a court case last year which meant Ibrutinib wouldn't go generic (legally) until 2032. I don't think that's changed? fiercepharma.com/pharma/don...

[64lusso in reply to bennevisplace]

Well shucks!! I'm always embarrassed at our annual insurance reviews to see my prescription cost being the highest out of all our 320 employees!

Thanks for the link, very enlightening.

[bennevisplace]

Ibrutinib provides examples of patent "maximisation" practised by big pharma.

heatinformatics.com/sites/d...